NCT01940640

Brief Summary

To date, the investigations in the field of the supplementation with DHA in premature babies have been focused on the study of neuronal and visual development, giving place to contradictory and ambiguous results, because they did not consider in many cases important aspects of this supplementation, such as the mother´s diet, dose, duration, etc., and precise studies have not been performed in the field of the oxidative damage, inflammation and bone development in this population. Hypothesis: If the composition of the mother´s milk is modified on the basis of her diet, a mother supplementation with high doses of DHA will increase proportionally the levels of this fatty acid in her milk, fact that will allows the premature newborn child receive a major dose of this fatty acid, and therefore this way, we will manage to improve the neuronal and visual development and to take part on the inflammatory process, oxidative damage and its evolution, together with the development or bone mass increase in the premature baby. Aims: Overall we aim to evaluate in a multidisciplinary way the effect of a mother supplementation during the lactation with high doses of DHA on the development and wellness of the premature newborn children. We try to deepen into the effect on the neuronal and visual development and to study, for the first time, the effect on the oxidative damage, pro- and antiinflammatory citoquines activity and bone metabolism in this group of newborn babies.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Jan 2012

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2012

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2013

Completed
2 days until next milestone

First Submitted

Initial submission to the registry

September 3, 2013

Completed
9 days until next milestone

First Posted

Study publicly available on registry

September 12, 2013

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2015

Completed
Last Updated

December 2, 2015

Status Verified

November 1, 2015

Enrollment Period

1.7 years

First QC Date

September 3, 2013

Last Update Submit

November 30, 2015

Conditions

Keywords

neonates, DHA

Outcome Measures

Primary Outcomes (1)

  • blood and milk samples

    Assessment of oxidative stress

    at delivery

Secondary Outcomes (1)

  • Blood

    at delivery

Study Arms (2)

DHA supplementation

EXPERIMENTAL

mothers consuming 900 mg DHA/day and their neonates.

Dietary Supplement: DHA

Control

ACTIVE COMPARATOR

follow on capsules without probiotics

Dietary Supplement: control

Interventions

DHADIETARY_SUPPLEMENT

We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).

Also known as: Docosahexaenoic acid
DHA supplementation
controlDIETARY_SUPPLEMENT

We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).

Also known as: Follow on capsules without probiotics
Control

Eligibility Criteria

Age1 Hour - 6 Months
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Preterm neonate, gestational age 30-34, PAEG (\>P10, \<P95), no pathologies.

You may not qualify if:

  • Lactose intolerance, systemic illness, multiple gestation, cromosomopathies, antibacterial therapy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital San Cecilio

Granada, Granada, 18071, Spain

Location

MeSH Terms

Interventions

Docosahexaenoic Acids

Intervention Hierarchy (Ancestors)

Fatty Acids, Omega-3Dietary Fats, UnsaturatedDietary FatsFatsLipidsFatty Acids, UnsaturatedFatty AcidsFish OilsOils

Study Officials

  • Julio J Ochoa, Ph.D.

    Universidad de Granada

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Julio J. Ochoa

Study Record Dates

First Submitted

September 3, 2013

First Posted

September 12, 2013

Study Start

January 1, 2012

Primary Completion

September 1, 2013

Study Completion

November 1, 2015

Last Updated

December 2, 2015

Record last verified: 2015-11

Locations